Navigation Links
AMRI Extends Long Term Supply Relationship with GE Healthcare
Date:12/6/2012

ALBANY, N.Y., Dec. 6, 2012 /PRNewswire/ -- AMRI (Nasdaq: AMRI) today announced the extension of a commercial supply relationship with GE Healthcare (NYSE: GE) for Aminobisamide Hydrochloride (ABA). Under the terms of the agreement, AMRI will supply ABA, an intermediate material used in diagnostic imaging agents. This substantial contract commitment positions AMRI as a strategic supplier to GE Healthcare.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Production will continue at AMRI's large scale manufacturing subsidiary located in Rensselaer, N.Y. The new contract extends through December 31, 2016, and replaces the existing supply contract between GE and AMRI that has been in effect since 2005.

"We are pleased to once again extend our long-term relationship with GE Healthcare," said AMRI Chairman, CEO and President Thomas E. D'Ambra, Ph.D. "The renewal of this relationship underscores the confidence that premier global pharmaceutical and health care companies have in AMRI's ability to meet their critical product needs."

Dr. D'Ambra continued, "The ABA product relationship with GE Healthcare has been an important one for AMRI since acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement. We continue to be pleased with the progress that we are making in our Large Scale Manufacturing business segment, the largest component of which is our Rensselaer site. We are adding new customers and new products at this facility, along with continuing the long term relationships, like GE Healthcare, that have formed the basis of our revenue stream. The extension of this key, long term agreement provides a consistent and high quality revenue source for this business unit through 2016."

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.

AMRI Rensselaer
AMRI's 23-acre Rensselaer site is located in New York State and provides contract cGMP manufacturing of bulk active pharmaceuticals and advanced intermediates for clinical phase scale-up requirements up to and including full scale commercial manufacturing. The facility, which hosts over 35 customer audits each year, maintains an excellent U.S. Federal Drug Administration (FDA) quality inspection record and is fully licensed by the U.S. Drug Enforcement Administration (DEA) to produce Schedule I, II, III, IV and V controlled substances. The site, which received its SafeBridge Potent Compound Safety Certification in 2010, has a state-of-art high-potency compound production facility that can handle quantities from grams to 120 kgs. Combining a scientifically strong staff with our highly experienced workforce allows the Rensselaer site to deliver its best to our customers. Currently, 26 Commercial Products are routinely manufactured from 25 kg individual batches to 7 metric ton annual campaigns.

Contacts
Investors – Michael Nolan, AMRI Chief Financial Officer, 518-512-2261
Media – Gina Monari, AMRI Communications, 518-512-2512


'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
2. In Observance of Veterans Day Reproductive Medicine Associates of New Jersey Extends "Helping Heroes Build Families" Program
3. Ansell Extends Antimicrobial Product Offering with New Non-latex Surgical Glove
4. New analog front end extends battery life of portable ECG equipment
5. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
6. GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit
7. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
8. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
9. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
10. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
11. Cardiac Science to Supply Q-Tel Data to AACVPR Cardiac Rehabilitation Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):